vs
Side-by-side financial comparison of Cushman & Wakefield Ltd. (CWK) and Solventum (SOLV). Click either name above to swap in a different company.
Cushman & Wakefield Ltd. is the larger business by last-quarter revenue ($2.9B vs $2.0B, roughly 1.5× Solventum). Solventum runs the higher net margin — 3.2% vs -0.8%, a 3.9% gap on every dollar of revenue. On growth, Cushman & Wakefield Ltd. posted the faster year-over-year revenue change (10.8% vs -3.7%). Cushman & Wakefield Ltd. produced more free cash flow last quarter ($234.3M vs $32.0M). Over the past eight quarters, Cushman & Wakefield Ltd.'s revenue compounded faster (15.5% CAGR vs -0.4%).
Cushman & Wakefield Inc. is an American global commercial real estate and property management services firm. The company's corporate headquarters is located in Chicago, Illinois. It is named after co-founders J. Clydesdale Cushman and Bernard Wakefield.
Solventum Corporation is an American health care company that was spun off from 3M on April 1, 2024.
CWK vs SOLV — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.9B | $2.0B |
| Net Profit | $-22.4M | $63.0M |
| Gross Margin | — | 51.4% |
| Operating Margin | 6.1% | 6.3% |
| Net Margin | -0.8% | 3.2% |
| Revenue YoY | 10.8% | -3.7% |
| Net Profit YoY | -119.8% | 103.2% |
| EPS (diluted) | $-0.10 | $0.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.9B | $2.0B | ||
| Q3 25 | $2.6B | $2.1B | ||
| Q2 25 | $2.5B | $2.2B | ||
| Q1 25 | $2.3B | $2.1B | ||
| Q4 24 | $2.6B | $2.1B | ||
| Q3 24 | $2.3B | $2.1B | ||
| Q2 24 | $2.3B | $2.1B | ||
| Q1 24 | $2.2B | $2.0B |
| Q4 25 | $-22.4M | $63.0M | ||
| Q3 25 | $51.4M | $1.3B | ||
| Q2 25 | $57.3M | $90.0M | ||
| Q1 25 | $1.9M | $137.0M | ||
| Q4 24 | $112.9M | $31.0M | ||
| Q3 24 | $33.7M | $122.0M | ||
| Q2 24 | $13.5M | $89.0M | ||
| Q1 24 | $-28.8M | $237.0M |
| Q4 25 | — | 51.4% | ||
| Q3 25 | — | 54.2% | ||
| Q2 25 | — | 54.4% | ||
| Q1 25 | — | 53.8% | ||
| Q4 24 | — | 53.9% | ||
| Q3 24 | — | 56.0% | ||
| Q2 24 | — | 54.6% | ||
| Q1 24 | — | 58.1% |
| Q4 25 | 6.1% | 6.3% | ||
| Q3 25 | 4.1% | 80.6% | ||
| Q2 25 | 4.9% | 9.9% | ||
| Q1 25 | 2.0% | 7.3% | ||
| Q4 24 | 6.6% | 6.6% | ||
| Q3 24 | 3.2% | 13.2% | ||
| Q2 24 | 3.1% | 11.7% | ||
| Q1 24 | 0.9% | 18.9% |
| Q4 25 | -0.8% | 3.2% | ||
| Q3 25 | 2.0% | 60.4% | ||
| Q2 25 | 2.3% | 4.2% | ||
| Q1 25 | 0.1% | 6.6% | ||
| Q4 24 | 4.3% | 1.5% | ||
| Q3 24 | 1.4% | 5.9% | ||
| Q2 24 | 0.6% | 4.3% | ||
| Q1 24 | -1.3% | 11.8% |
| Q4 25 | $-0.10 | $0.37 | ||
| Q3 25 | $0.22 | $7.22 | ||
| Q2 25 | $0.25 | $0.51 | ||
| Q1 25 | $0.01 | $0.78 | ||
| Q4 24 | $0.49 | $0.18 | ||
| Q3 24 | $0.14 | $0.70 | ||
| Q2 24 | $0.06 | $0.51 | ||
| Q1 24 | $-0.13 | $1.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $784.2M | $878.0M |
| Total DebtLower is stronger | $2.7B | $5.0B |
| Stockholders' EquityBook value | $2.0B | $5.0B |
| Total Assets | $7.7B | $14.3B |
| Debt / EquityLower = less leverage | 1.40× | 1.00× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $784.2M | $878.0M | ||
| Q3 25 | $634.4M | $1.6B | ||
| Q2 25 | $618.2M | $492.0M | ||
| Q1 25 | $623.2M | $534.0M | ||
| Q4 24 | $793.3M | $762.0M | ||
| Q3 24 | $775.4M | $772.0M | ||
| Q2 24 | $567.3M | $897.0M | ||
| Q1 24 | $553.5M | $996.0M |
| Q4 25 | $2.7B | $5.0B | ||
| Q3 25 | $2.8B | $5.1B | ||
| Q2 25 | $3.0B | $7.8B | ||
| Q1 25 | $3.0B | $7.9B | ||
| Q4 24 | $3.0B | $8.0B | ||
| Q3 24 | $3.1B | $8.1B | ||
| Q2 24 | $3.1B | $8.3B | ||
| Q1 24 | $3.2B | $8.3B |
| Q4 25 | $2.0B | $5.0B | ||
| Q3 25 | $2.0B | $5.0B | ||
| Q2 25 | $1.9B | $3.6B | ||
| Q1 25 | $1.8B | $3.3B | ||
| Q4 24 | $1.8B | $3.0B | ||
| Q3 24 | $1.7B | $3.2B | ||
| Q2 24 | $1.6B | $2.9B | ||
| Q1 24 | $1.6B | $3.9B |
| Q4 25 | $7.7B | $14.3B | ||
| Q3 25 | $7.7B | $14.0B | ||
| Q2 25 | $7.6B | $15.1B | ||
| Q1 25 | $7.4B | $14.5B | ||
| Q4 24 | $7.5B | $14.5B | ||
| Q3 24 | $7.5B | $14.7B | ||
| Q2 24 | $7.3B | $14.6B | ||
| Q1 24 | $7.5B | $14.7B |
| Q4 25 | 1.40× | 1.00× | ||
| Q3 25 | 1.45× | 1.03× | ||
| Q2 25 | 1.57× | 2.14× | ||
| Q1 25 | 1.70× | 2.43× | ||
| Q4 24 | 1.73× | 2.71× | ||
| Q3 24 | 1.81× | 2.54× | ||
| Q2 24 | 1.91× | 2.90× | ||
| Q1 24 | 1.96× | 2.16× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $257.3M | $95.0M |
| Free Cash FlowOCF − Capex | $234.3M | $32.0M |
| FCF MarginFCF / Revenue | 8.0% | 1.6% |
| Capex IntensityCapex / Revenue | 0.8% | 3.2% |
| Cash ConversionOCF / Net Profit | — | 1.51× |
| TTM Free Cash FlowTrailing 4 quarters | $293.0M | $-10.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $257.3M | $95.0M | ||
| Q3 25 | $235.5M | $76.0M | ||
| Q2 25 | $9.6M | $169.0M | ||
| Q1 25 | $-162.0M | $29.0M | ||
| Q4 24 | $115.2M | $219.0M | ||
| Q3 24 | $196.1M | $169.0M | ||
| Q2 24 | $21.8M | $355.0M | ||
| Q1 24 | $-125.1M | $442.0M |
| Q4 25 | $234.3M | $32.0M | ||
| Q3 25 | $225.0M | $-21.0M | ||
| Q2 25 | $300.0K | $59.0M | ||
| Q1 25 | $-166.6M | $-80.0M | ||
| Q4 24 | $105.9M | $92.0M | ||
| Q3 24 | $186.7M | $76.0M | ||
| Q2 24 | $10.0M | $297.0M | ||
| Q1 24 | $-135.6M | $340.0M |
| Q4 25 | 8.0% | 1.6% | ||
| Q3 25 | 8.6% | -1.0% | ||
| Q2 25 | 0.0% | 2.7% | ||
| Q1 25 | -7.3% | -3.9% | ||
| Q4 24 | 4.0% | 4.4% | ||
| Q3 24 | 8.0% | 3.7% | ||
| Q2 24 | 0.4% | 14.3% | ||
| Q1 24 | -6.2% | 16.9% |
| Q4 25 | 0.8% | 3.2% | ||
| Q3 25 | 0.4% | 4.6% | ||
| Q2 25 | 0.4% | 5.1% | ||
| Q1 25 | 0.2% | 5.3% | ||
| Q4 24 | 0.4% | 6.1% | ||
| Q3 24 | 0.4% | 4.5% | ||
| Q2 24 | 0.5% | 2.8% | ||
| Q1 24 | 0.5% | 5.1% |
| Q4 25 | — | 1.51× | ||
| Q3 25 | 4.58× | 0.06× | ||
| Q2 25 | 0.17× | 1.88× | ||
| Q1 25 | -85.26× | 0.21× | ||
| Q4 24 | 1.02× | 7.06× | ||
| Q3 24 | 5.82× | 1.39× | ||
| Q2 24 | 1.61× | 3.99× | ||
| Q1 24 | — | 1.86× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CWK
| Equity Method Investment Nonconsolidated Investee Or Group Of Investees | $1.8B | 61% |
| Other | $1.1B | 39% |
SOLV
| Infection Prevention And Surgical Solutions | $752.0M | 38% |
| Cost Of Software And Rentals | $508.0M | 25% |
| Health Information Systems Segment | $347.0M | 17% |
| Dental Solutions Segment | $343.0M | 17% |
| Related Party | $14.0M | 1% |
